# Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

> **NCT04700436** · PHASE4 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 146 (actual)

## Conditions studied

- Endocrine System Diseases
- Nutritional and Metabolic Diseases
- Diabetes Mellitus, Type 2
- Dyslipidemias

## Interventions

- **DRUG:** Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
- **DRUG:** Suvast tablet 10 mg (Rosuvastatin 10 mg)

## Key facts

- **NCT ID:** NCT04700436
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-03
- **Primary completion:** 2021-05-28
- **Final completion:** 2024-02-13
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700436, "Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04700436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*